Intranasal INNA-051 for Prevention of COVID-19 in Adults

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Timeline

Start

2022-03-01

Primary completion

2022-12-31

Completion

2022-12-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications